A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.
Also called NCT01301066
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 252 participants
- Registry
-
NCT01301066
-
- Other papers using this trial's data
- Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV
- Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients
- Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01301066. Randomized; double masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-04-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- Condition
- Dyslipidemia
- Intervention (Drug)
- Pitavastatin
- Intervention (Drug)
- Pravastatin
- Lead sponsor
- Kowa Research Institute, Inc.
- Collaborator
- Kowa Pharmaceuticals America, Inc.
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01301066- Content hash
0fee5f386b00305b7c2daa3b3888ed7170d3e4ce52a1c25066e02e51caec95e7